Candel Therapeutics, Inc. Contracts & Agreements
34 Contracts & Agreements
- Business Finance (10 contracts)
- Business Operations (1)
- Human Resources (14)
- Intellectual Property (6)
- Real Estate (2)
- Uncategorized (1)
- Consulting by and between Candel Therapeutics, Inc. and Jason A. Amello, dated as of January 12, 2024 (Filed With SEC on March 28, 2024)
- First Amendment to Loan and Security Agreement by and between Candel Therapeutics, Inc. and Silicon Valley Bank, dated June 14, 2023 (Filed With SEC on August 10, 2023)
- Amendment to Exclusive License Agreement by and between Candel Therapeutics, Inc. and Periphagen, Inc., dated June 7, 2023 (Filed With SEC on August 10, 2023)
- Employment Agreement by and between Candel Therapeutics and Jason A. Amello dated September 21, 2022 (Filed With SEC on November 10, 2022)
- Employment Agreement by and between Candel Therapeutics and Seshu Tyagarajan dated April 14, 2022 (Filed With SEC on August 5, 2022)
- Employment Agreement by and between Candel Therapeutics and Seshu Tyagarajan dated April 14, 2022 (Filed With SEC on May 12, 2022)
- Employment Agreement by and between Candel Therapeutics and Francesca Barone dated February 3, 2022 (Filed With SEC on March 29, 2022)
- Description of Securities (Filed With SEC on March 29, 2022)
- Loan and Security Agreement by and between the Registrant and Silicon Valley Bank, dated February 24, 2022 (Filed With SEC on March 29, 2022)
- Consulting Agreement by and between Candel Therapeutics, Inc. and Susan Stewart dated October 19, 2021 (Filed With SEC on March 29, 2022)
- Employment Agreement by and between Advantagene, Inc. d/b/a Candel Therapeutics and John Canepa dated December 1, 2020 (Filed With SEC on July 16, 2021)
- Lease of Premises at 117 Kendrick Street, Needham, Massachusetts by and between 117 Kendrick DE, LLC and the Registrant dated as of February 4, 2019 (Filed With SEC on July 16, 2021)
- Exclusive Patent License Agreement by and between Advantagene, Inc. and The Brigham and Womens Hospital, Inc. dated September 15, 2020 (Filed With SEC on July 16, 2021)
- Exclusive License Agreement by and between Advantagene, Inc. and Ventagen, LLC dated March 1, 2014 (Filed With SEC on July 16, 2021)
- Form of Indemnification Agreement (Filed With SEC on July 16, 2021)
- Consulting Agreement by and between Candel Therapeutics, Inc. and Susan Stewart dated January 4, 2020 (Filed With SEC on July 16, 2021)
- Employment Agreement by and between Advantagene, Inc. d/b/a Candel Therapeutics and Nathan Caffo dated September 24, 2020 (Filed With SEC on July 16, 2021)
- Amended and Restated Employment Agreement by and between Advantagene, Inc. and Laura Aguilar, M.D., Ph.D. dated November 13, 2018 (Filed With SEC on July 16, 2021)
- Form of Underwriting Agreement (Filed With SEC on July 16, 2021)
- Specimen Common Stock Certificate (Filed With SEC on July 16, 2021)
- Form of November 2018 Unconditional Warrant to Purchase Common Stock (Filed With SEC on July 16, 2021)
- Form of November 2018 Conditional Warrant to Purchase Common Stock (Filed With SEC on July 16, 2021)
- 2015 Stock Plan, as amended, and forms of award agreements thereunder (Filed With SEC on July 16, 2021)
- 2021 Stock Option and Incentive Plan and forms of award agreements thereunder (Filed With SEC on July 16, 2021)
- Senior Executive Cash Incentive Bonus Plan (Filed With SEC on July 16, 2021)
- Employee Stock Purchase Plan (Filed With SEC on July 16, 2021)
- Employment Agreement by and between Advantagene, Inc. d/b/a Candel Therapeutics and Paul Peter Tak, M.D., Ph.D. dated September 12, 2020 (Filed With SEC on July 16, 2021)
- Amended and Restated Employment Agreement by and between Advantagene, Inc. and Estuardo Aguilar-Cordova dated November 13, 2018 (Filed With SEC on July 16, 2021)
- Second Amended and Restated Investors Rights Agreement by and among the Registrant and certain of its stockholders dated March 19, 2019 (Filed With SEC on June 25, 2021)
- Lease of Premises at 117 Kendrick Street, Needham, Massachusetts by and between 117 Kendrick DE, LLC and the Registrant dated as of February 4, 2019 (Filed With SEC on June 25, 2021)
- Exclusive Patent License Agreement by and between Advantagene, Inc. and The Brigham and Womens Hospital, Inc. dated September 15, 2020 (Filed With SEC on June 25, 2021)
- Exclusive License Agreement by and between Advantagene, Inc., d/b/a Candel Therapeutics and Periphagen, Inc. dated December 9, 2019 (Filed With SEC on June 25, 2021)
- Exclusive License Agreement by and between Advantagene, Inc. and Ventagen, LLC dated March 1, 2014 (Filed With SEC on June 25, 2021)
- Form of Warrant to Purchase Series A Convertible Preferred Stock (Filed With SEC on June 25, 2021)
